These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 32573825)

  • 21. Real-World Experience With Tofacitinib Dose De-Escalation in Patients With Moderate and Severe Ulcerative Colitis.
    Yu A; Ha NB; Shi B; Cheng YW; Mahadevan U; Beck KR
    Clin Gastroenterol Hepatol; 2023 Nov; 21(12):3115-3124.e3. PubMed ID: 37187323
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Can we move directly from 5-ASA to a biologic agent in ulcerative colitis?
    Hindryckx P; Novak G
    Best Pract Res Clin Gastroenterol; 2018; 32-33():9-15. PubMed ID: 30060944
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Allopurinol in addition to 5-aminosalicylic acid based drugs for the maintenance treatment of ulcerative colitis.
    Järnerot G; Ström M; Danielsson A; Kilander A; Lööf L; Hultcrantz R; Löfberg R; Florén C; Nilsson A; Broström O
    Aliment Pharmacol Ther; 2000 Sep; 14(9):1159-62. PubMed ID: 10971232
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-Term Benefit of Mesalamine Granules for Patients Who Achieved Corticosteroid-Induced Ulcerative Colitis Remission.
    Lichtenstein GR; Gordon GL; Zakko S; Murthy U; Sedghi S; Pruitt R; Barrett AC; Bortey E; Paterson C; Forbes WP
    Dig Dis Sci; 2016 Jan; 61(1):221-9. PubMed ID: 26563167
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of Long-Term Mesalamine Therapy on Cancer-Associated Gene Expression in Colonic Mucosa of Patients with Ulcerative Colitis.
    Bajpai M; Seril DN; Van Gurp J; Geng X; Alvarez J; Minacapelli CD; Gorin S; Das KK; Poplin E; Cheng J; Amenta PS; Das KM
    Dig Dis Sci; 2019 Mar; 64(3):740-750. PubMed ID: 30478770
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of weekend 5-aminosalicylic acid (mesalazine) enema as maintenance therapy for ulcerative colitis: results from a randomized controlled study.
    Yokoyama H; Takagi S; Kuriyama S; Takahashi S; Takahashi H; Iwabuchi M; Takahashi S; Kinouchi Y; Hiwatashi N; Tsuji I; Shimosegawa T
    Inflamm Bowel Dis; 2007 Sep; 13(9):1115-20. PubMed ID: 17455207
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment of new-onset ulcerative colitis and ulcerative proctitis: a retrospective study.
    Richter JM; Kushkuley S; Barrett JA; Oster G
    Aliment Pharmacol Ther; 2012 Aug; 36(3):248-56. PubMed ID: 22690748
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Longitudinal non-adherence predicts treatment escalation in paediatric ulcerative colitis.
    Carmody JK; Plevinsky J; Peugh JL; Denson LA; Hyams JS; Lobato D; LeLeiko NS; Hommel KA
    Aliment Pharmacol Ther; 2019 Oct; 50(8):911-918. PubMed ID: 31373712
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical and biological predictors of response to standardised paediatric colitis therapy (PROTECT): a multicentre inception cohort study.
    Hyams JS; Davis Thomas S; Gotman N; Haberman Y; Karns R; Schirmer M; Mo A; Mack DR; Boyle B; Griffiths AM; LeLeiko NS; Sauer CG; Keljo DJ; Markowitz J; Baker SS; Rosh J; Baldassano RN; Patel A; Pfefferkorn M; Otley A; Heyman M; Noe J; Oliva-Hemker M; Rufo PA; Strople J; Ziring D; Guthery SL; Sudel B; Benkov K; Wali P; Moulton D; Evans J; Kappelman MD; Marquis MA; Sylvester FA; Collins MH; Venkateswaran S; Dubinsky M; Tangpricha V; Spada KL; Saul B; Wang J; Serrano J; Hommel K; Marigorta UM; Gibson G; Xavier RJ; Kugathasan S; Walters T; Denson LA
    Lancet; 2019 Apr; 393(10182):1708-1720. PubMed ID: 30935734
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-term intermittent treatment with low-dose 5-aminosalicylic enemas is efficacious for remission maintenance in ulcerative colitis.
    Piodi LP; Ulivieri FM; Cermesoni L; Cesana BM
    Scand J Gastroenterol; 2004 Feb; 39(2):154-7. PubMed ID: 15000277
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prevalence and Risk Factors for Therapy Escalation in Ulcerative Colitis in the Swiss IBD Cohort Study.
    Safroneeva E; Vavricka SR; Fournier N; Straumann A; Rogler G; Schoepfer AM
    Inflamm Bowel Dis; 2015 Jun; 21(6):1348-58. PubMed ID: 25806845
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mesalamine restores angiogenic balance in experimental ulcerative colitis by reducing expression of endostatin and angiostatin: novel molecular mechanism for therapeutic action of mesalamine.
    Deng X; Tolstanova G; Khomenko T; Chen L; Tarnawski A; Szabo S; Sandor Z
    J Pharmacol Exp Ther; 2009 Dec; 331(3):1071-8. PubMed ID: 19762547
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact and risk factors of non-adherence to 5-aminosalicylates in quiescent ulcerative colitis evaluated by an electronic management system.
    Ballester MP; Marti-Aguado D; Fullana M; Bosca-Watts MM; Tosca J; Romero E; Sanchez A; Navarro-Cortes P; Anton R; Mora F; Minguez M
    Int J Colorectal Dis; 2019 Jun; 34(6):1053-1059. PubMed ID: 30963247
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Review article: evolving concepts in treatment and disease modification in ulcerative colitis.
    Hanauer SB
    Aliment Pharmacol Ther; 2008 Mar; 27 Suppl 1():15-21. PubMed ID: 18307645
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Medication adherence and persistence in the treatment of Canadian ulcerative colitis patients: analyses with the RAMQ database.
    Lachaine J; Yen L; Beauchemin C; Hodgkins P
    BMC Gastroenterol; 2013 Jan; 13():23. PubMed ID: 23363459
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of outcomes of continuation/discontinuation of 5-aminosalicylic acid after initiation of anti-tumor necrosis factor-alpha therapy in patients with inflammatory bowel disease.
    Choi YI; Kim TJ; Park DK; Chung JW; Kim KO; Kwon KA; Kim YJ
    Int J Colorectal Dis; 2019 Oct; 34(10):1713-1721. PubMed ID: 31471699
    [TBL] [Abstract][Full Text] [Related]  

  • 37. AGA Technical Review on the Management of Mild-to-Moderate Ulcerative Colitis.
    Singh S; Feuerstein JD; Binion DG; Tremaine WJ
    Gastroenterology; 2019 Feb; 156(3):769-808.e29. PubMed ID: 30576642
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and Safety of Beclomethasone Dipropionate versus 5-Aminosalicylic Acid in the Treatment of Ulcerative Colitis: A Systematic Review and Meta-Analysis.
    Zhao X; Li N; Ren Y; Ma T; Wang C; Wang J; You S
    PLoS One; 2016; 11(8):e0160500. PubMed ID: 27501314
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Randomized clinical trial: pharmacokinetics and safety of multimatrix mesalamine for treatment of pediatric ulcerative colitis.
    Cuffari C; Pierce D; Korczowski B; Fyderek K; Van Heusen H; Hossack S; Wan H; Edwards AY; Martin P
    Drug Des Devel Ther; 2016; 10():593-607. PubMed ID: 26893546
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Factors associated with early outcomes following standardised therapy in children with ulcerative colitis (PROTECT): a multicentre inception cohort study.
    Hyams JS; Davis S; Mack DR; Boyle B; Griffiths AM; LeLeiko NS; Sauer CG; Keljo DJ; Markowitz J; Baker SS; Rosh J; Baldassano RN; Patel A; Pfefferkorn M; Otley A; Heyman M; Noe J; Oliva-Hemker M; Rufo P; Strople J; Ziring D; Guthery SL; Sudel B; Benkov K; Wali P; Moulton D; Evans J; Kappelman MD; Marquis A; Sylvester FA; Collins MH; Venkateswaran S; Dubinsky M; Tangpricha V; Spada KL; Britt A; Saul B; Gotman N; Wang J; Serrano J; Kugathasan S; Walters T; Denson LA
    Lancet Gastroenterol Hepatol; 2017 Dec; 2(12):855-868. PubMed ID: 28939374
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.